Blockchain Registration Transaction Record

NeOnc's NEO100 Shows Promising Phase 2a Results; FDA Meeting Planned

NeOnc Technologies' NEO100 shows positive Phase 2a results in recurrent brain cancer, with median OS of 26 months. FDA Type B meeting planned for registrational path.

This news matters because it offers hope for patients with recurrent brain cancer, a condition with limited treatment options and poor prognosis. The positive Phase 2a data for NEO100 suggests a potential new therapy that could significantly extend survival compared to current salvage treatments. For investors, it signals a potential advancement toward regulatory approval and commercialization, which could lead to substantial returns. Moreover, the progress of NEO212 and the expansion into other tumor types indicate a growing pipeline that could address multiple unmet medical needs, making NeOnc a key player in oncology innovation.